Ganetespib, an HSP90 inhibitor, kills Epstein–Barr virus (EBV)-infected B and T cells and reduces the percentage of EBV-infected cells in the blood

References

• Longnecker L, Kieff E, Cohen JI. Epstein-Barr Virus. In: Knipe DM, Howley PM, Cohen JI, Griffith DE, Lamb RA, Martin MA, Racaniello V, Roizman B, editors. Fields virology, 6th ed. Philadelphia, (PA): Lippincott Williams & Wilkins; 2013. p 1898–1959.
   Google Scholar
• Trepel J, Mollapour M, Giaccone G, et al. Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer. 2010;10:537–549.
   PubMed Web of Science ®Google Scholar
• Nagy PD, Wang RY, Pogany J, et al. Emerging picture of host chaperone and cyclophilin roles in RNA virus replication. Virology. 2011;411:374–382.
   PubMed Web of Science ®Google Scholar
• Knox C, Luke GA, Blatch GL, et al. Heat shock protein 40 (Hsp40) plays a key role in the virus life cycle. Virus Res. 2011;160:15–24.
   PubMed Web of Science ®Google Scholar
• Cheung RK, Dosch HM. The growth transformation of human B cells involves superinduction of hsp70 and hsp90. Virology. 1993;193:700–708.
   PubMed Web of Science ®Google Scholar
• Kotsiopriftis M, Tanner JE, Alfieri C. Heat shock protein 90 expression in Epstein-Barr virus-infected B cells promotes gammadelta T-cell proliferation in vitro. J Virol. 2005;79:7255–7261.
   PubMed Web of Science ®Google Scholar
• Alsayed Y, Leleu X, Leontovich A, et al. Proteomics analysis in post-transplant lymphoproliferative disorders. Eur J Haematol. 2008;81:298–303.
   PubMed Web of Science ®Google Scholar
• Sun X, Barlow EA, Ma S, et al. Hsp90 inhibitors block outgrowth of EBV-infected malignant cells in vitro and in vivo through an EBNA1-dependent mechanism. Proc Natl Acad Sci USA. 2010;107:3146–3151.
   PubMed Web of Science ®Google Scholar
• Murata T, Iwata S, Siddiquey MN, et al. Heat shock protein 90 inhibitors repress latent membrane protein 1 (LMP1) expression and proliferation of Epstein-Barr virus-positive natural killer cell lymphoma. PLoS One. 2013;8:e63566.
   PubMed Web of Science ®Google Scholar
• Suzuki M, Takeda T, Nakagawa H, et al. The heat shock protein 90 inhibitor BIIB021 suppresses the growth of T and natural killer cell lymphomas. Front Microbiol. 2015;6:280.
   PubMed Web of Science ®Google Scholar
• Jeon YK, Park CH, Kim KY, et al. The heat-shock protein 90 inhibitor, geldanamycin, induces apoptotic cell death in Epstein-Barr virus-positive NK/T-cell lymphoma by Akt down-regulation. J Pathol. 2007;213:170–179.
   PubMed Web of Science ®Google Scholar
• Chan KC, Ting CM, Chan PS, et al. A novel Hsp90 inhibitor AT13387 induces senescence in EBV-positive nasopharyngeal carcinoma cells and suppresses tumor formation. Mol Cancer. 2013;12:128.
   PubMed Web of Science ®Google Scholar
• Sun X, Bristol JA, Iwahori S, et al. Hsp90 inhibitor 17-DMAG decreases expression of conserved herpesvirus protein kinases and reduces virus production in Epstein-Barr virus-infected cells. J Virol. 2013;87:10126–10138.
   PubMed Web of Science ®Google Scholar
• Nayar U, Lu P, Goldstein RL, et al. Targeting the Hsp90-associated viral oncoproteome in gammaherpesvirus-associated malignancies. Blood. 2013;122:2837–2847.
   PubMed Web of Science ®Google Scholar
• Takada K, Horinouchi K, Ono Y, et al. An Epstein-Barr virus-producer line Akata: establishment of the cell line and analysis of viral DNA. Virus Genes. 1991;5:147–156.
   PubMed Web of Science ®Google Scholar
• Gregory CD, Rowe M, Rickinson AB. Different Epstein-Barr virus-B cell interactions in phenotypically distinct clones of a Burkitt's lymphoma cell line. J Gen Virol. 1990;71:1481–1495.
   PubMed Web of Science ®Google Scholar
• Menezes J, Leibold W, Klein G, et al. Establishment and characterization of an Epstein-Barr virus (EBC)-negative lymphoblastoid B cell line (BJA-B) from an exceptional, EBV-genome-negative African Burkitt's lymphoma. Biomedicine. 1975;22:276–284.
   PubMedGoogle Scholar
• Calender A, Billaud M, Aubry JP, et al. Epstein-Barr virus (EBV) induces expression of B-cell activation markers on in vitro infection of EBV-negative B-lymphoma cells. Proc Natl Acad Sci USA. 1987;84:8060–8064.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Nagata H, Ikeuchi T, et al. Common cytological and cytogenetic features of Epstein-Barr virus (EBV)-positive natural killer (NK) cells and cell lines derived from patients with nasal T/NK-cell lymphomas, chronic active EBV infection and hydroa vacciniforme-like eruptions. Br J Haematol. 2003;121:805–814.
   PubMed Web of Science ®Google Scholar
• Ramakrishnan R, Donahue H, Garcia D, et al. Epstein-Barr virus BART9 miRNA modulates LMP1 levels and affects growth rate of nasal NK T cell lymphomas. PLoS One. 2011;6:e27271.
   Google Scholar
• Klion AD, Mejia R, Cowen EW, et al. Chronic active Epstein-Barr virus infection: a novel cause of lymphocytic variant hypereosinophilic syndrome. Blood. 2013;121:2364–2366.
   PubMed Web of Science ®Google Scholar
• Calattini S, Sereti I, Scheinberg P, et al. Detection of EBV genomes in plasmablasts/plasma cells and non-B cells in the blood of most patients with EBV lymphoproliferative disorders by using Immuno-FISH. Blood. 2010;116:4546–4559.
   PubMed Web of Science ®Google Scholar
• Rowe M, Young LS, Crocker J, et al. Epstein-Barr virus (EBV)-associated lymphoproliferative disease in the SCID mouse model: implications for the pathogenesis of EBV-positive lymphomas in man. J Exp Med. 1991;173:147–158.
   PubMed Web of Science ®Google Scholar
• Zou J, Guo Y, Guettouche T, et al. Repression of heat shock transcription factor HSF1 activation by HSP90 (HSP90 complex) that forms a stress-sensitive complex with HSF1. Cell. 1998;94:471–480.
   PubMed Web of Science ®Google Scholar
• Jhaveri K, Modi S. Ganetespib: research and clinical development. Onco Targets Ther. 2015;8:1849–1858.
   PubMed Web of Science ®Google Scholar
• Proia DA, Bates RC. Ganetespib and HSP90: translating preclinical hypotheses into clinical promise. Cancer Res. 2014;74:1294–1300.
   PubMed Web of Science ®Google Scholar
• Nagaraju GP, Mezina A, Shaib WL, et al. Targeting the Janus-activated kinase-2-STAT3 signalling pathway in pancreatic cancer using the HSP90 inhibitor ganetespib. Eur J Cancer. 2016;52:109–119.
   PubMed Web of Science ®Google Scholar
• Friedland JC, Smith DL, Sang J, et al. Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes. Invest New Drugs. 2014;32:14–24.
   PubMed Web of Science ®Google Scholar
• Wu X, Marmarelis ME, Hodi FS. Activity of the heat shock protein 90 inhibitor ganetespib in melanoma. PLoS One. 2013;8:e56134.
   Google Scholar
• Chaigne-Delalande B, Li FY, O'Connor GM, et al. Mg2+ regulates cytotoxic functions of NK and CD8 T cells in chronic EBV infection through NKG2D. Science. 2013;341:186–191.
   PubMed Web of Science ®Google Scholar